TNFRSF17 and Miyoshi myopathy: BCMA targeted CAR-T cells frequently induce dramatic complete responses in 39 to 67% of patients with relapsed and refractory MM (14, 35), however these therapies are associated with frequent relapses with no evidence of a plateau in the survival curve (36, 37).